Recombinant poxvirus compositions and methods of inducing immune responses
US5942235A · kind A · utility
54Cited by
14References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 2, 1995 |
| Grant date | Aug 24, 1999 |
| Priority date | — |
| Expiry date | Jun 2, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN.gamma.; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.